Mergers & Acquisitions ·
Passage Bio, Inc. filed an amended and restated merger agreement with Remix Therapeutics, Inc., dated September 2…
PASGPassage BIO, Inc.
Passage Bio, Inc. filed an amended and restated merger agreement with Remix Therapeutics, Inc., dated September 2, 2026, to implement a two-step merger structure while maintaining the original economic terms and aggregate equity values. The transaction involves a concurrent private placement financing of approximately $70.0 million, funded through pre-funded warrants purchased at $1.3860 each or Remix common stock at $1.3861 per share. Both companies' boards have approved and recommended the merger to their respective shareholders, with an outside closing date of December 24, 2026. Passage Bio, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases.